ADPT Relative Valuation
ADPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADPT is overvalued; if below, it's undervalued.
Historical Valuation
Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.00 is considered Undervalued compared with the five-year average of -12.80. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 33.07 to 36.37 according to relative valuation methord. Compared to the current price of 11.35 USD , Adaptive Biotechnologies Corp is Undervalued By 65.68%.
Relative Value
Fair Zone
33.07-36.37
Current Price：11.35
65.68%
Undervalued
-13.71
PE
1Y
3Y
5Y
Trailing
Forward
-42.51
EV/EBITDA
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBITDA of -42.51. The 5-year average EV/EBITDA is -17.21. The thresholds are as follows: Strongly Undervalued below -47.36, Undervalued between -47.36 and -32.29, Fairly Valued between -2.13 and -32.29, Overvalued between -2.13 and 12.95, and Strongly Overvalued above 12.95. The current Forward EV/EBITDA of -42.51 falls within the Undervalued range.
-13.75
EV/EBIT
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBIT of -13.75. The 5-year average EV/EBIT is -10.64. The thresholds are as follows: Strongly Undervalued below -30.60, Undervalued between -30.60 and -20.62, Fairly Valued between -0.66 and -20.62, Overvalued between -0.66 and 9.31, and Strongly Overvalued above 9.31. The current Forward EV/EBIT of -13.75 falls within the Historic Trend Line -Fairly Valued range.
7.39
PS
Adaptive Biotechnologies Corp. (ADPT) has a current PS of 7.39. The 5-year average PS is 14.64. The thresholds are as follows: Strongly Undervalued below -17.27, Undervalued between -17.27 and -1.31, Fairly Valued between 30.60 and -1.31, Overvalued between 30.60 and 46.55, and Strongly Overvalued above 46.55. The current Forward PS of 7.39 falls within the Historic Trend Line -Fairly Valued range.
-34.58
P/OCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/OCF of -34.58. The 5-year average P/OCF is -16.73. The thresholds are as follows: Strongly Undervalued below -47.02, Undervalued between -47.02 and -31.88, Fairly Valued between -1.59 and -31.88, Overvalued between -1.59 and 13.56, and Strongly Overvalued above 13.56. The current Forward P/OCF of -34.58 falls within the Undervalued range.
-132.59
P/FCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/FCF of -132.59. The 5-year average P/FCF is -24.73. The thresholds are as follows: Strongly Undervalued below -80.38, Undervalued between -80.38 and -52.55, Fairly Valued between 3.09 and -52.55, Overvalued between 3.09 and 30.91, and Strongly Overvalued above 30.91. The current Forward P/FCF of -132.59 falls within the Strongly Undervalued range.
Adaptive Biotechnologies Corp (ADPT) has a current Price-to-Book (P/B) ratio of 8.70. Compared to its 3-year average P/B ratio of 3.20 , the current P/B ratio is approximately 172.01% higher. Relative to its 5-year average P/B ratio of 4.62, the current P/B ratio is about 88.20% higher. Adaptive Biotechnologies Corp (ADPT) has a Forward Free Cash Flow (FCF) yield of approximately -5.66%. Compared to its 3-year average FCF yield of -18.99%, the current FCF yield is approximately -70.22% lower. Relative to its 5-year average FCF yield of -14.32% , the current FCF yield is about -60.51% lower.
8.82
P/B
Median3y
3.20
Median5y
4.62
-5.36
FCF Yield
Median3y
-18.99
Median5y
-14.32
Competitors Valuation Multiple
The average P/S ratio for ADPT's competitors is 73.90, providing a benchmark for relative valuation. Adaptive Biotechnologies Corp Corp (ADPT) exhibits a P/S ratio of 7.39, which is -90.00% above the industry average. Given its robust revenue growth of 25.24%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADPT increased by 148.72% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.22 to -11.53.
The secondary factor is the Revenue Growth, contributed 25.24%to the performance.
Overall, the performance of ADPT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Adaptive Biotechnologies Corp (ADPT) currently overvalued or undervalued?
What is Adaptive Biotechnologies Corp (ADPT) fair value?
How does ADPT's valuation metrics compare to the industry average?
What is the current P/B ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 07 2025?
What is the current FCF Yield for Adaptive Biotechnologies Corp (ADPT) as of Aug 07 2025?
What is the current Forward P/E ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 07 2025?